Inpefa
Inpefa (sotagliflozin) is a brand-name oral medication used to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure. It is also indicated for adults with type 2 diabetes, chronic kidney disease, and cardiovascular disease to reduce cardiovascular and heart failure-related outcomes. Inpefa works by inhibiting SGLT1 and SGLT2 proteins, which helps the kidneys remove excess glucose and sodium from the body.
Inpefa is a heart failure medication that reduces cardiovascular death and hospitalization risk in adults with heart failure or certain cardiovascular conditions.
Key facts at a glance
- RxNorm
- 2638684
- Generic
- Inpefa
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Inpefa is prescribed to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure (with reduced or preserved ejection fraction). It is also indicated for adults with type 2 diabetes, chronic kidney disease, and cardiovascular disease risk factors.
Inpefa is a dual SGLT1 and SGLT2 inhibitor. It works by blocking these glucose and sodium co-transporter proteins in the kidneys and intestines, promoting glucose excretion, sodium removal, and improved cardiac function. This mechanism helps reduce fluid overload and decreases the workload on the heart.
Inpefa carries a boxed warning for diabetic ketoacidosis (DKA) in patients with type 2 diabetes. Common side effects include urinary tract infections, genital fungal infections, and volume depletion. It should not be used in patients with type 1 diabetes or those with severe kidney impairment. Inpefa is taken orally once daily, with or without food.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy